Xue Y, Zhu L, Karan S, Locker J, Branch C, Zhang J
Commun Biol. 2025; 8(1):278.
PMID: 39987265
PMC: 11846996.
DOI: 10.1038/s42003-025-07662-3.
Mzoughi S, Schwarz M, Wang X, Demircioglu D, Ulukaya G, Mohammed K
Nat Genet. 2025; 57(2):402-412.
PMID: 39930084
PMC: 11821538.
DOI: 10.1038/s41588-024-02058-1.
Hamed A, Hua K, Trinh Q, Simons B, Marioni J, Stein L
Nature. 2025; 638(8050):499-509.
PMID: 39743595
PMC: 11821533.
DOI: 10.1038/s41586-024-08356-2.
Cheung E, Strathdee D, Stevenson D, Coomes J, Blyth K, Vousden K
Proc Natl Acad Sci U S A. 2024; 121(50):e2416076121.
PMID: 39636862
PMC: 11648893.
DOI: 10.1073/pnas.2416076121.
Verstappe J, Skrypek N, De Coninck J, Soen B, Taminau J, Tatari M
iScience. 2024; 27(11):111169.
PMID: 39555401
PMC: 11567922.
DOI: 10.1016/j.isci.2024.111169.
BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.
Khalizieva A, Moser S, Bouwman P, Jonkers J
Genes Dev. 2024; 39(1-2):86-108.
PMID: 39510841
PMC: 11789497.
DOI: 10.1101/gad.352083.124.
Polyclonality overcomes fitness barriers in Apc-driven tumorigenesis.
Sadien I, Adler S, Mehmed S, Bailey S, Sawle A, Couturier D
Nature. 2024; 634(8036):1196-1203.
PMID: 39478206
PMC: 11525183.
DOI: 10.1038/s41586-024-08053-0.
Cancer cell stiffening via CoQ and UBIAD1 regulates ECM signaling and ferroptosis in breast cancer.
Tosi G, Paoli A, Zuccolotto G, Turco E, Simonato M, Tosoni D
Nat Commun. 2024; 15(1):8214.
PMID: 39294175
PMC: 11410950.
DOI: 10.1038/s41467-024-52523-y.
Mechanisms that clear mutations drive field cancerization in mammary tissue.
Ciwinska M, Messal H, Hristova H, Lutz C, Bornes L, Chalkiadakis T
Nature. 2024; 633(8028):198-206.
PMID: 39232148
PMC: 11374684.
DOI: 10.1038/s41586-024-07882-3.
Medulloblastomas Initiated by Homologous Recombination Defects in Mice.
Lu H, Wang Y, Chaudhary S, Balaga V, Ke H, Shi F
Am J Pathol. 2024; 194(11):2007-2022.
PMID: 39168365
PMC: 11816638.
DOI: 10.1016/j.ajpath.2024.07.018.
Loss Enhances Disease Progression in a Murine Model of Osteosarcoma.
Fatema K, Wang Y, Pavek A, Larson Z, Nartker C, Plyler S
Cancers (Basel). 2024; 16(15).
PMID: 39123453
PMC: 11311538.
DOI: 10.3390/cancers16152725.
Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment.
Abboud E, Chrayteh D, Boussetta N, Dalle H, Malerba M, Wu T
Nat Commun. 2024; 15(1):6718.
PMID: 39112467
PMC: 11306357.
DOI: 10.1038/s41467-024-50993-8.
SMYD5 methylation of rpL40 links ribosomal output to gastric cancer.
Park J, Wu J, Szkop K, Jeong J, Jovanovic P, Husmann D
Nature. 2024; 632(8025):656-663.
PMID: 39048817
PMC: 11625416.
DOI: 10.1038/s41586-024-07718-0.
Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy.
Knott E, Kim E, Kim E, Freire R, Medina J, Wang Y
Cells. 2024; 13(13.
PMID: 38994972
PMC: 11240577.
DOI: 10.3390/cells13131120.
Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer.
Tsutsumi E, Macy A, LoBello J, Hastings K, Kim S
PLoS One. 2024; 19(7):e0304194.
PMID: 38968186
PMC: 11226078.
DOI: 10.1371/journal.pone.0304194.
Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma.
Ueno T, Otani S, Date Y, Katsuma Y, Nagayoshi Y, Ito T
Cancer Sci. 2024; 115(9):2961-2971.
PMID: 38924236
PMC: 11462974.
DOI: 10.1111/cas.16255.
Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion.
Faraldo M, Romagnoli M, Wallon L, Dubus P, Deugnier M, Fre S
Breast Cancer Res. 2024; 26(1):91.
PMID: 38835038
PMC: 11151721.
DOI: 10.1186/s13058-024-01851-4.
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
Dibitetto D, Liptay M, Vivalda F, Dogan H, Gogola E, Gonzalez Fernandez M
Nat Commun. 2024; 15(1):4430.
PMID: 38789420
PMC: 11126719.
DOI: 10.1038/s41467-024-48715-1.
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Spitzer A, Gritsch S, Nomura M, Jucht A, Fortin J, Raviram R
Cancer Cell. 2024; 42(5):904-914.e9.
PMID: 38579724
PMC: 11096020.
DOI: 10.1016/j.ccell.2024.03.008.
The CLCF1-CNTFR axis drives an immunosuppressive tumor microenvironment and blockade enhances the effects of established cancer therapies.
Sweet-Cordero E, Marini K, Champion E, Lee A, Young I, Leung S
Res Sq. 2024; .
PMID: 38562778
PMC: 10984090.
DOI: 10.21203/rs.3.rs-4046823/v1.